CLYM
Eliem Therapeutics Inc (CLYM)
Healthcare • NASDAQ • $17.28+1.53%
- Symbol
- CLYM
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $17.28
- Daily Change
- +1.53%
- Market Cap
- $937.93M
- Trailing P/E
- N/A
- Forward P/E
- -15.47
- 52W High
- $17.00
- 52W Low
- $1.54
- Analyst Target
- $22.57
- Dividend Yield
- N/A
- Beta
- 0.08
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutic…
Company websiteResearch CLYM on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.